




**ΚΥΠΡΙΑΚΟ ΓΡΑΦΕΙΟ ΔΙΠΛΩΜΑΤΩΝ
ΕΥΡΕΣΙΤΕΧΝΙΑΣ
THE PATENT OFFICE OF CYPRUS**

**ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ CY1369
PUBLICATION NUMBER**

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
ΓΡΑΦΕΙΟΥ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
ΗΝΩΜΕΝΟΥ ΒΑΣΙΛΕΙΟΥ
UK PATENT OFFICE
PUBLICATION NUMBER GB2083474

Το έγγραφο που παρουσιάζεται πιο κάτω καταχωρήθηκε στο «Γραφείο Διπλωμάτων Ευρεσιτεχνίας» στην Αγγλία σύμφωνα με το Νόμο Κεφ. 266 πριν την 1^η Απριλίου 1998. Δημοσίευση έγινε μετέπειτα από το Γραφείο Διπλωμάτων Ευρεσιτεχνίας του Ηνωμένου Βασιλείου μόνο στην Αγγλική γλώσσα.

**The document provided hereafter was filed at "The Patent Office"
in England under the law CAP.266 before the 1st of April 1998.
It was published afterwards by the UK patent office only in English.**

(12) UK Patent Application (19) GB (11) 2 083 474 A

(21) Application No 8127018
(22) Date of filing 7 Sep 1981
(30) Priority data
(31) 184677
(32) 8 Sep 1980
(33) United States of America (US)

(43) Application published
24 Mar 1982

(51) INT CL³
C07D 401/14 A61K
31/495 (C07D 401/14
211/40 213/74 241/04
295/14)

(52) Domestic classification
C2C 1175 1530 1532
1626 211 215 220 225
226 22Y 246 247 250 251
252 25Y 28X 29X 29Y
30Y 313 314 31Y 326 337
339 351 352 364 36Y 386
388 43X 440 624 62Y
635 672 676 69Y 761 763
802 80Y AA MD TP WB
WH

(56) Documents cited
US 3717634A
US 3907801A
US 3976776A

(58) Field of search
C2C


(71) Applicant
Bristol-Myers Company,
345 Park Avenue, New
York 10022, United
States of America

(72) Inventors
Davis L. Temple,
Joseph P. Tevich,
Walter G. Lobeck

(74) Agents
Langner Parry,
52—54 High Holborn,
London, WC1V 6RR

(54) N-[(4-[3-Substituted
Pyridyl]piperazino)
alkyl]azaspirodecanediones

(57) Novel compounds of the formula



and the pharmaceutically acceptable
acid addition salts thereof wherein R¹
and R² are independently H or methyl
and R³ is cyano or methoxy are
psychotropic.

GB 2 083 474 A

SPECIFICATION


N-[(4-[3-Substituted Pyridyl]Piperazino)Alkyl]Azaspirodecanediones

Field of the Invention

This invention is concerned with chemical compounds having three heterocyclic components of which the central component is a piperazine ring which is substituted at the 1- and 4- positions by other heterocyclic systems one of which is pyridine (Class 544, Subclass 364).

Summary of the Invention

The compounds of this invention have Formula I wherein R¹ and R² are selected from hydrogen and methyl, and R³ is cyano or methoxy. The pharmaceutically acceptable acid addition salts are also included.




Formula I

These compounds are psychotropic agents which have advantages for the latter purpose due to their lack of extrapyramidal and adrenergic blocking effects in psychotropically effective doses. They are prepared by the application of known synthetic methods to the appropriate starting materials.

Description of the Prior Art

The structures of four compounds of the prior art, Compound Nos. 1, 2, 3, and 6, and three compounds of the present invention, Compound Nos. 4, 5, and 7 are illustrated in the following table.

Structures



	Cmpd. No.	n	B	
20	1	2	2-pyridyl	20
	2	3	6-methoxy-2-pyridyl	
	3	4	2-pyridyl	
	4	4	3-cyano-2-pyridyl	
25	5	4	3-cyano-2-pyridyl*	25
	6	4	2-pyrimidyl	
	7	4	3-methoxy-2-pyridyl	

* 3-Methylpiperazine is substituted for piperazine as the central ring; B is located in the piperazine 1-position.

Compound Nos. 1, 2, 3, and 6 are the subjects, with others of the same structural type, of a publication by Wu, et al., entitled "Psychosedative Agents. 2. 8-(4-Substituted 1-Piperazinylalkyl)-8-azaspiro[4.5]decane-7,9-diones", Journal of Medicinal Chemistry, 1972, Vol. 15, No. 5, pages 477—479, in which they are referred to by the same numbers as herein, and of U.S. Patent No. 3,717,634 patented February 20, 1973, U.S. Patent No. 3,907,801 patented September 23, 1975, and U.S. Patent No. 3,976,776, each by Wu, et al., where these substances are described as psychotropic agents having properties typical of the major tranquilizers such as chlorpromazine. The later two patents are divisions of the earlier. The disclosures of U.S. Patent Nos. 3,717,634, 3,907,801, and 3,976,776 are incorporated herein by reference.

Compound Nos. 3 and 6 in the foregoing table are referred to in the Wu, et al. patents as preferred members of the series. Refer, to Column 3, lines 1—12, of the second Wu, et al. patent. A more remotely related group of compounds is disclosed in an earlier patent and publication of Wu, et al., U.S. 3,398,151 patented August 20, 1968 and Journal of Medicinal Chemistry, Vol. 12, pages 876—881 (1969) which refer to compounds having the general formula shown in the table, but in which the B substituent is phenyl or substituted phenyl.

U.S. Patent No. 4,182,763 patented February 8, 1980 by Casten, et al. refers to the anxiolytic use of Compound No. 6 where it is referred to by the name buspirone. The disclosure of the Casten, et al. patent is also incorporated herein by reference. U.S. Food and Drug Administration approval for the use of buspirone for the treatment of anxiety neurosis was being sought as of the filing date hereof.

5 Detailed Description of the Invention

Biological test data related to the psychotropic action of Compound Nos. 1—7 and attendant side effects of CNS depression and *alpha*-adrenergic blocking action are shown in the following table. Values obtained for chlorpromazine are included for reference.

Biological Tests

10	I.	CAR-ED ₅₀ (mg/kg. of body weight) fasted rat treated orally (psychotropic).	10						
	II.	CAR-ED ₅₀ (mg/kg. of body weight) fed rat treated intra-peritoneally (psychotropic).							
	III.	AED _{0.3} (mg/kg. of body weight) activity cage mouse treated orally (CNS depression).							
	IV.	AED _{0.3} (mg/kg. of body weight) activity cage, mouse treated intraperitoneally (CNS depression).							
15	V.	Receptor binding assay, IC ₅₀ in nM, tritiated spirone as ligand (psychotropic).	15						
	VI.	Receptor binding assay, IC ₅₀ in nM, tritiated WB-4101 as ligand (<i>alpha</i> -adrenergi blockade).							
	VII.	IC ₅₀ (mcg/ml) <i>alpha</i> -adrenergic receptor blocking action <i>in vitro</i> -rat seminal vesicle-1-norepinephrine as spasmogen.							
	<i>Cmpd. No.</i>	<i>I</i>	<i>II</i>	<i>III</i>	<i>IV</i>	<i>V</i>	<i>VI</i>	<i>VII</i>	
20	1	—	22.6	—	41	—	—	2.08	20
	2	—	>50	82	7.4	—	48	0.073	
	3	34	2.8	10	2.6	960	280	0.335	
	4	24	—	97	—	110	360	—	
	5	85	—	—	—	400	—	—	
25	6	48	4.3	92	33	120	1400	3.5	25
	7	55	—	—	—	100*	65	—	
	Chlorpromazine	39	4.8	—	3.6	40	31	0.0132	

* Average of two determinations.

Tests I and II refer to the conditioned avoidance response. Data with respect to Test II were obtained by the method described in the above Wu, et al. patents and publications in which trained rats were maintained on a standard laboratory diet and were treated intraperitoneally with the test drug. Test I is a modification of the same conditioned avoidance response test except that fasted rats were employed and the animals were treated orally. Comparison of the data from Tests I and II for Compound Nos. 3, 6, and chlorpromazine suggests that the values obtained treating fasted rats orally are approximately 8 to 12 times (indicating less activity) those obtained employing the intraperitoneal route of administration with fed rats.

Test IV involves measurement of spontaneous motor activity of mice as a reflection of the CNS depressant or sedative side effects of the test compound. It was carried out according to the method described in the foregoing Wu, et al. 1972 publication. Test III is similar except that the mice were treated orally. By reference to the data from Tests III and IV for Compound Nos. 2, 3, and 6, it is evident that the intraperitoneal route of administration reflects several-fold stronger activity than the oral route. The AED_{0.3} reflects approximately 50% reduction in spontaneous motor activity.

Test VII is an *in vitro* measurement of *alpha*-adrenergic receptor blocking action employing the isolated seminal vesicle of the rat. *Alpha*-adrenergic receptor blocking action is an undesired side effect of the major tranquilizers such as chlorpromazine. The strong *alpha*-adrenergic blocking activity thereof is reflected by the data in the table. The method of Test VII is that described in the foregoing Wu, et al. 1972 publication. The IC₅₀ value is the concentration of the test compound in solution which inhibits by 50% the contractile response of the tissue strip to 1-norepinephrine. A low value represents high activity.

Tests V and VI are receptor binding assays which measure the ability of a compound to prevent the binding of a radiolabeled ligand to specific high affinity sites in brain tissue. According to the state of the art, various ligands have been identified with aspects of CNS function or potential for side effects. The ability of a compound to inhibit labeled ligand binding *in vitro* is considered to be a reflection of the compound's ability to effect the corresponding CNS function or side effect *in vivo*.

Test V is a dopamine binding assay which reflects neuroleptic activity (Burt, Creese, and Snyder, Molec. Pharmacol. 12:800 (1976); Burt, Creese, and Snyder, Science 196: 326 (1977); Creese, Burt, and Snyder, Science 192: 481 (1976)). The corpus striatum of male Sprague-Dawley rats (Charles River Laboratories) is employed as the test tissue. The radiolabeled ligand is tritiated spiperone. In Test V any compound more active than clozapine (IC₅₀=1000 nM) is considered to have potential utility.

Thus, any value less than 1000 nM in Test V represents potential neuroleptic utility.

Test VI employs tritiated (2,6-dimethoxyphenoxyethyl)amino-methyl-1,4-benzodioxane, also known as WB-4101, as radiolabeled ligand and receptor tissue of the cerebral cortex (Sprague-Dawley rats). WB-4101 is an *alpha*-adrenergic blocking agent and has a high affinity for *alpha*-adrenergic receptors in the cerebral cortex (Crews, et al., Science 202: 322 (1978); Rosenblatt, et al., Brain Res. 160: 186 (1979); U'Prichard, et al., Science 199: 197 (1978); U'Prichard, et al., Molec. Pharmacol. 73: 454 (1977)). In this test compounds having less than 1/10th the potency of phentolamine, which exerts IC₅₀ of 10 nM, are considered to be inactive. Thus, any compound having a value in excess of 100 nM is considered inactive.

Compound No. 4 is the preferred compound of the present invention. The substance has good potency in Tests I and V reflecting neuroleptic action, and low potency in Tests III and VI reflecting lack of sedative action and lack of *alpha*-adrenergic blocking action. It is distinguished from the prior art, and particularly Compound No. 3 the most structurally similar compound, with regard to neuro-leptic potency in Test V, lack of sedative action which is high for Compound No. 3 (Tests III and IV). A low propensity for those undesired actions of Compound No. 4 is evident by comparing its values in Tests III and VI to Compound No. 6 which is known to have low activities of those types.

The other prior art pyridines, Compound Nos. 1 and 2, are very substantially less active in the conditioned avoidance response test reflected by the data for Test II. Compound No. 2 is in addition a relatively strong *alpha*-adrenergic blocking agent (Tests VI and VII).

Compound Nos. 4, 6, and 7 are each inactive at oral doses of 200 mg/kg. in the rat catalepsy test (Costall, B. and Naylor, R. J., Psychopharmacologia, 34, 233—241 (1974)) signifying low potential for provoking extrapyramidal symptoms (EPS). That dose of Compound No. 7, however, constituted the ALD₅₀ dose for rats. In mice the ALD₅₀ of Compound No. 7 was determined to be 500 mg/kg. of body weight. Chlorpromazine exhibits ED₅₀=4.1 mg/kg. in the rat catalepsy test in correlation with its known propensity for EPS.


The compounds of the present invention may be administered to mammals to exert their tranquilizer or neuroleptic and anxiolytic effects in the same way and in similar dosage amounts as are suitable for buspirone, and the other pyrimidines and pyridines claimed in the cited Wu, et al. patents. Information with respect to dosage, pharmaceutical formulations and administration is presented in the above cited U.S. Patent Nos. 3,976,776 and 4,182,763. Likewise, the synthetic methods of U.S. 3,907,801 for the synthesis of the prior art pyridine Compounds 1, 2, and 3 are applicable to the synthesis of the compounds of the present invention and reference should be made to U.S. 3,907,801 for general information in this regard.

Description of Specific Embodiments

In the following procedures temperatures are expressed in degrees centigrade (°). Melting points are uncorrected. The nuclear magnetic resonance (NMR) spectral characteristics for both the hydrogen nuclei (H NMR) and the 13 molecular weight carbon isotope nuclei (¹³C NMR) refer to chemical shifts (δ) expressed as parts per million (ppm) versus tetramethylsilane (TMS) as reference standard. The relative area reported for the various shifts in the H NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type in the molecule. The nature of the shifts as to multiplicity is reported as broad singlet (bs), singlet (s), multiplet (m), doublet (d), triplet (t), or doublet of doublets (dd) with coupling constants (J) reported where appropriate in both the H NMR and the ¹³C NMR spectral data. The format is H NMR (solvent): δ (relative area, multiplicity, J value), and ¹³C NMR (solvent): δ multiplicity. Abbreviations employed are DMSO-d₆ (deuterodimethyl-sulfoxide), CDCl₃ (deuteriochloroform), and are otherwise conventional. The infrared (IR) spectral descriptions include only absorption wave umbers (cm⁻¹) having functional group identification value. The IR determinations were employed either using potassium bromide (KBr) as diluent, or with liquids using the film technique (film). The elemental analyses are reported as percent by weight.

Procedure 1

8-[4-(1-Piperazinyl)butyl]-8-azaspiro[4.5]decane-7,9-dione




The following materials are charged to a 1 liter reaction flask containing 500 ml. of toluene, and the mixture is refluxed for 18 hrs.

3,3-tetramethyleneglutaramide	33.4 g., 0.2 moles
1,4-dibromobutane	43.2 g., 0.2 moles
Potassium carbonate	103.7 g., 0.75 moles

After the reflux period was completed, 64.6 g. (0.75 mole) of piperazine was added and heating at reflux was continued for an additional 7 hrs. The mixture was then filtered hot to remove insoluble material, and the filtrate was allowed to stand at room temperature overnight. Unreacted piperazine separated as a crystalline solid which was removed by filtration. The solvent was removed from the filtrate by vacuum distillation, and the residue was distilled at 180—210°/0.1 mmHg, yield 23.56 g. (38%). Examination of the NMR spectrum indicated contamination of the product with a small amount of piperazine.

Procedure 2

2-[4-[4-(7,9-Dioxo-8-azaspiro[4.5]decan-8-yl)butyl]-1-piperazinyl]pyridine-3-carbonitrile



The product of Procedure 1, 5.0 g. (0.0163 mole) and 2.26 g. (0.0163 mole) of 2-chloro-3-cyanopyridine, 1.65 g. (0.0163 mole) triethylamine, and 40 ml. of ethanol were placed in a pressure vessel and the void space flushed with nitrogen before sealing. The vessel was then heated at 150°C for 5 hrs. and allowed to cool overnight. The contents were removed and partitioned between 50 ml. of chloroform and 50 ml. of water. The chloroform layer was separated, dried, and the solvent removed by distillation yielding 6.27 g. of an oil. A portion of the latter weighing 5.68 g. was dissolved in chloroform and absorbed on a column containing 240 g. of silica. The column was developed first with 2 l. of chloroform which resulted in the removal of essentially none of the desired material and then with 2.5 l. of chloroform containing 2% by volume of ethanol. The first half of the $\text{CHCl}_3/\text{EtOH}$ eluate yielded 3.4 g. of an oil the NMR spectrum of which corresponded to the desired product. The oil, 3.14 g., was dissolved in 25 ml. of ethanol, the solution chilled in an ice bath, and 2.56 ml. of 2.99 N ethanolic hydrochloric acid was added. The amount of hydrochloric acid employed was the stoichiometric amount required for formation of the monohydrochloride salt of the desired product. The salt failed to precipitate and the solution was concentrated to dryness and the residue triturated with ether resulting in partial crystallization thereof. The solid was dissolved in 250 ml. of acetone, filtered, and the solution poured into 300 ml. of ether resulting in precipitation of the desired monohydrochloride salt. It was dried *in vacuo* at the reflux temperature of toluene; yield 2.31 g., m.p. 180—182°.

Anal. Found: C, 62.04; H, 7.29; N, 15.58.


IR (KBr): 1130, 1240, 1360, 1440, 1580, 1670, 1720, 2220, 2450, and 2950 cm^{-1} .

^1H NMR ($\text{DMSO}-d_6$): 1.54 (12, m); 2.65 (4, s); 3.12 (4, m); 3.66 (6, m); 4.27 (2, m); 7.04 (1, dd, 7.8 Hz, 4.8 Hz); 8.14 (1, dd, 7.8 Hz, 2.9 Hz); 8.46 (1, dd, 4.8 Hz, 2.0 Hz).

^{13}C NMR ($\text{DMSO}-d_6$): 20.41, 23.66, 24.76, 36.82, 37.80, 39.08, 43.82, 44.71, 50.24, 55.00, 95.75, 115.99, 117.26, 144.19, 151.96, 159.76, 172.09.

Procedure 3

8-[4-(2-Methyl-4-[phenylmethyl]-1-piperazinyl)-butyl]-8-azaspiro[4.5]decane-7,9-dione



2-Methyl-4-benzylpiperazine dimaleate was prepared according to the method of Cignarella, et al., *il. Farmaco. Ed. Sc.*, Volume 34, page 820. This material, 16.9 g. (0.04 mole), was refluxed in 400 ml. of acetonitrile as reaction medium with 12.1 g. (0.04 mole) of 8-(1-bromo-4-butyl)-8-azaspiro[4.5]decane-7,9-dione, 16.6 g. (0.12 mole) of potassium carbonate, and a few crystals of potassium iodide for 20 hrs. The solvent was removed by distillation *in vacuo*, the residue dissolved in 150 ml. of ether, insoluble material removed by filtration, and the ether removed by distillation *in vacuo*. The residue was an oil weighing 17.2 g. which was dissolved in 100 ml. of ethanol, acidified with 11.06 ml. of 7.6 N hydrochloric acid and set aside to cool. The desired material crystallized as the dihydrochloride salt 1/4 molecular proportion hydrate and was recovered by filtration; yield 15.58 g., (80%), m.p. 238—240°.


Anal. Found: C, 61.45; H, 7.97; N, 8.35; H₂O 0.57.

IR. 1130, 1360, 1450, 1670, 1720, 2450, and 2950 cm⁻¹.

¹H NMR (DMSO-d₆): 1.36 (3, d, 6.0 Hz); 1.50 (12, m); 2.60 (4, s); 3.50 (11, m); 4.33 (2, s); 3.90 (2, bs).

- 5 The starting material 8-(1-bromo-4-butyl)-8-azaspiro[4.5]decane-7,9-dione was prepared as described in Procedure 1 prior to addition of the piperazine reactant except that the amount of 1,4-dibromobutane employed was doubled. The product was isolated after removing insoluble material by filtration of the hot reaction mixture, evaporating the toluene from the filtrate, and distilling the residue *in vacuo*, b.p. 160—167°/0.1 mmHg, yield 35.2 g. (58%). 5

10 **Procedure 4** 8-[4-(2-Methyl-1-piperaziny)butyl]-8-azaspiro[4.5]decane-7,9-dione 10




- 15 The product of Procedure 3, 15.58 g. (0.031 mole) was suspended in 110 ml. of water and hydrogenated over 2 g. of a 10% palladium-on-carbon catalyst at 67 psig and room temperature. After hydrogen absorption had ceased, the catalyst was removed by filtration and the water was removed from the filtrate by vacuum distillation. The residue was crystallized from 40 ml. of ethanol and the product dried to constant weight; yield 12.49 g. of the dihydrochloride salt, m.p. 215—217°. 15

Anal. Found: C, 54.48; H, 8.21; N, 10.64.

IR (KBr): 1125, 1360, 1370, 1400, 1670, 1722, 2660, and 2950 cm⁻¹.

- 20 ¹H NMR (DMSO-d₆): 1.39 (3, d, 6.0 Hz); 1.50 (12, m); 2.61 (4, s); 3.40 (11, m); 10.10 (3, bs). 20
¹³C NMR (DMSO-d₆): 13.50 q, 19.95 t, 23.61 t, 24.65 t, 36.77, 37.60, 39.05, 43.79 t, 44.50, 50.61 t, 54.00 d, 176.34 s.

25 **Procedure 5** 2-[4-[4-(7,9-Dioxo-8-azaspiro[4.5]decan-8-yl)butyl]-3-methyl-1-piperaziny]pyridine-3-carbonitrile 25




- 30 The product of Procedure 4, 3.38 g. (0.0105 mole) was caused to react with 1.46 g. (0.0105 mole) of 2-chloro-3-cyanopyridine in the presence of 1.06 g. (0.0105 mole) of triethylamine in 40 ml. of ethanol in a pressure vessel as described in Procedure 2. The crude product, 3.58 g., was recovered as an oil which was dissolved in 30 ml. of ethanol and treated with 2 molecular proportions of ethanolic hydrogen chloride. The solvent was removed by distillation, and the residue was dried by azeotropic distillation with benzene which resulted in crystallization of the desired product as the monohydrochloride, m.p. 181—183°. 30

Anal. Found: C, 62.45; H, 7.48; N, 15.16.

- 35 IR (KBr): 1135, 1350, 1440, 1580, 1670, 1720, 2220, 2460, and 2950 cm⁻¹. 35
¹H NMR (DMSO-d₆): 1.50 (15 m); 2.62 (4, s); 3.50 (9, m); 4.16 (2, m); 7.02 (1, dd, 7.8 Hz, 4.9 Hz); 8.14 (1, dd, 7.8 Hz, 1.9 Hz); 8.45 (1, dd, 4.9 Hz, 1.9 Hz); 11.70 (1, bs).

40 **Procedure 6** 8-[4-(3-Methyl-1-piperaziny)butyl]-8-azaspiro[4.5]decane-7,9-dione 40



A mixture of 8-(1-bromo-4-butyl)-8-azaspiro[4.5]decan-7,9-dione prepared as described in Procedure 3, 8.14 g. (0.027 moles), and 5.41 g. (0.054 moles) of 2-methylpiperazine was heated at reflux in 40 ml. of toluene overnight. The by-product 2-methylpiperazine hydrobromide was removed by filtration and the solvent was distilled from the filtrate *in vacuo*. The residue was dissolved in chloroform and extracted with 100 ml. of 1.5N aqueous hydrochloric acid. The product was recovered from the aqueous extract by neutralization with sodium hydroxide and extraction into chloroform. After drying and evaporation of the chloroform, the crude product was obtained as a residue weighing 9.76 g. It was distilled *in vacuo*, b.p. 180—185°C./0.01 mmHg; yield, 6.22 g. A portion of this material weighing 1.5 g. was dissolved in 10 ml. of ethanol and converted to the hydrochloride salt by treatment with sufficient ethanolic hydrogen chloride to provide the dihydrochloride salt. The solvent was distilled *in vacuo*, and the residue was crystallized from a mixture of 10 ml. of ethanol and 35 ml. of acetone yielding the monohydrochloride which crystallized as the hemihydrate; yield, 1.05 g., m.p. 196—198°C.

Anal. Found: C, 53.61; H, 8.37; N, 10.06; H₂O 2.57.


IR (KBr): 1125, 1215, 1360, 1440, 1670, 1725, 2700, and 2950 cm⁻¹.

¹H NMR (DMSO-d₆): 1.51 (15, m); 2.80 (4, s); 3.85 (11, m); 10.60 (3, bs).

¹³C NMR (DMSO-d₆): 15.14 q, 20.41 t, 23.61 t, 24.56 t, 36.78 t, 37.73, 39.04, 39.30, 43.78 t, 46.90 d, 47.90 t, 52.15 t, 55.10 t, 172.10 s.

Procedure 7

2-[4-[(7,9-Dioxo-8-azaspiro[4.5]decan-8-yl)-butyl]-2-methyl-1-piperazinyl]pyridine-3-carbonitrile



The product of Procedure 6 is allowed to react with 2-chloro-3-cyanopyridine as described in Procedures 2 and 5 to yield this substance.

25 Procedure 8

2-Chloro-3-methoxypyridine

3-methoxy-2-(1H)pyridone, 10 g. (0.08 mole), 12.3 g. (0.08 mole) of phosphorous oxychloride, and 11.9 g. (0.08 mole) of N,N-diethylaniline are combined in a suitable reaction vessel and heated at reflux for 20 hrs. The reaction mixture was allowed to cool, and was then mixed with 200 ml. of water and ice. The aqueous mixture was extracted with ether and the extracts dried over magnesium sulfate. The drying agent was then removed by filtration and the solvent was removed from the filtrate by distillation *in vacuo*. The residue was extracted with 160 ml. of boiling hexane and the hexane extracts decanted from the residue while still hot. The hexane solution was cooled in ice resulting in precipitation of the desired produce, weight 7.5 g., m.p. 46—48°.

35 Procedure 9

4-(3-Methoxy-2-pyridinyl)piperazine

2-Chloro-3-methoxypyridine, 7g., (0.05 mole) was allowed to react with 21.5 g. (0.25 moles) of piperazine in the presence of 34.5 g. (0.25 mole) of pulverized potassium carbonate employing 150 ml. of amyl alcohol as reaction medium. The mixture was heated at reflux in a round bottom flask after drying the reaction mixture by distillation. A reflux period of 20 hrs. following elimination of the water was employed. The reaction mixture was filtered while hot and the solvent was removed from the filtrate by distillation. The residue was triturated with chloroform and 1 g. of solid was removed by filtration. The chloroform was removed from the filtrate by distillation yielding 3.88 g. of the desired product which was purified by distillation, b.p. 120—124°/0.1 mmHg.


Anal. C, 61.72; H, 8.03; N, 20.83.

IR (film): 790, 1020, 1110, 1210, 1240, 1450, 1470, 1590, 2835, and 2940 cm⁻¹.

¹H NMR (CDCl₃): 1.91 (1, s); 3.05 (4, m); 3.36 (4, m); 3.84 (3, s); 6.77 (1, dd, 5.0 Hz, 7.8 Hz); 7.00 (1, dd, 1.9 Hz, 7.8 Hz); 7.85 (1, dd, 1.9 Hz, 5.0 Hz).

Procedure 10

8-[4-[4-(3-Methoxy-2-pyridinyl)-1-piperazinyl]-butyl]-8-azaspiro[4.5]decane-7,9-dione




4-(3-Methoxy-2-pyridinyl)piperazine, 4.87 g. (0.025 mole), was allowed to react with 7.62 g. (0.025 mole) of 8-(1-bromo-4-butyl)-8-azaspiro[4.5]decane-7,9-dione prepared as described in Procedure 3 in the presence of 2.53 g. (0.025 moles) of triethylamine employing 60 ml. of ethanol as reaction medium. The reaction was carried out in a pressure vessel at a temperature of 150°C. for 6-1/2 hours in the same fashion as described in Procedure 2. After allowing the reaction vessel to cool to room temperature, it was opened and the reaction mixture was concentrated by distillation of the solvent *in vacuo*. The residue was dissolved in chloroform and washed with 30 ml. of aqueous 1 N sodium hydroxide, and then with 40 ml. of water. The chloroform solution was dried over magnesium sulfate and the chloroform removed by distillation *in vacuo*, yielding 10.49 g. of the desired product. This material was purified by column chromatography employing a column containing 250 g. of silica developed with chloroform containing 5% by volume of ethanol. The product was isolated from the eluate and weighed 5.96 g. This crude material was converted to the dihydrochloride salt by dissolving in 50 ml. of ethanol and treating the solution with hydrogen chloride. Insoluble material was removed by filtration and the filtrate was treated with 200 ml. of ether which resulted in precipitation of the dihydrochloride salt of the desired product, m.p. 194—196°, yield 5.56 g.

Anal. C, 57.02; H, 7.62; N, 11.46.
IR (KBr): 790, 1000, 1130, 1240, 1345, 1440, 1600, 1665, 1725, 2560, 2860, and 2950 cm^{-1} .
H NMR ($\text{DMSO}-d_6$): 1.55 (12, m); 2.65 (4, s); 3.12 (4, m); 3.64 (6, m); 3.91 (3, s); 4.24 (2, m); 7.12 (1, dd, 5.3 Hz, 8.0 Hz); 7.62 (1, m); 7.78 (1, m); 11.40 (1, bs); 11.90 (1, bs).

Claims

1. A compound selected from the group consisting of those having the formula



and the pharmaceutically acceptable acid addition salts thereof wherein R^1 and R^2 are selected from the group consisting of hydrogen and methyl, and R^3 is selected from the group consisting of cyano and methoxy.

2. The compound of Claim 1, 2-[4-[4-(7,9-dioxo-8-azaspiro[4.5]decan-8-yl)butyl]-1-piperazinyl]pyridine-3-carbonitrile or a pharmaceutically acceptable acid addition salt thereof.

3. The compound of Claim 1, 2-[4-[4-(7,9-dioxo-8-azaspiro[4.5]decan-8-yl)-3-methyl-1-piperazinyl]pyridine-3-carbonitrile or a pharmaceutically acceptable acid addition salt thereof.


4. The compound of Claim 1, 8-[4-[4-(3-methoxy-2-pyridinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione.

5. The process for eliciting a tranquilizer effect in a psychotic mammal which comprises administering to said mammal a non-toxic neuroleptically effective dose of from 0.01 to 40 mg/kg. of body weight of said mammal of a compound claimed in Claim 1 by the oral or a parenteral route.


6. A method for the palliative treatment of neurosis in which anxiety symptoms are prominent which comprises administering a non-toxic anxiolytically effective dose of a compound claimed in Claim 1 to a neurotic patient by the oral or a parenteral route.

7. A pharmaceutical composition in dosage unit form suitable for systemic administration to a mammalian host comprising a pharmaceutical carrier and an amount of a compound claimed in Claim 1 to provide an effective daily dose of from 0.01 to 40 mg/kg. of body weight of said host.

8. A process for preparing a compound of the formula



and the pharmaceutically acceptable acid addition salts thereof, wherein R^1 and R^2 are independently of each other a hydrogen or methyl group, which comprises contacting a compound of the formula



- 5 with a 2-halo-3-cyanopyridine at elevated temperature, and, if desired, forming an acid addition salt of the resulting compound. 5
9. A pharmaceutical compound as defined in Claim 1 for use in a method of treatment of the human or animal body.
10. A compound according to Claim 8 for use as a tranquiliser.
- 10 11. A compound according to Claim 1, substantially as hereinbefore specifically described in each of the examples for the use hereinbefore specifically described. 10
12. A compound as described in Claim 1, substantially as hereinbefore specifically described in each of the examples.
13. A pharmaceutical composition according to Claim 7, substantially as hereinbefore specifically described in examples. 15
- 15 14. A process for making a compound as defined in Claim 1, substantially as hereinbefore specifically described in the examples.
- 15 15. A compound when produced by a process as claimed in Claim 8.